Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
Condition(s):Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8Last Updated:March 5, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8Last Updated:March 5, 2024Active, not recruiting
Condition(s):Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell LymphomaLast Updated:February 15, 2024Active, not recruiting
Condition(s):Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Recurrent Cervical Carcinoma; Stage IV Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVB Cervical Cancer AJCC v6 and v7Last Updated:March 5, 2024Active, not recruiting
Condition(s):Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Neuroendocrine Tumor G1; Neuroendocrine Tumor G2; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1Last Updated:February 15, 2024Active, not recruiting
Condition(s):Chronic Lymphocytic Leukemia; Plasma Cell MyelomaLast Updated:May 6, 2023Completed
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:June 28, 2023Terminated
Condition(s):Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable MelanomaLast Updated:March 6, 2024Active, not recruiting
Condition(s):Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable MelanomaLast Updated:March 6, 2024Active, not recruiting
Condition(s):Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7Last Updated:June 1, 2023Completed
Condition(s):Borderline Ovarian Serous Tumor; Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Serous AdenocarcinomaLast Updated:February 15, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.